SSG
CARM

Summit Securities Group’s Carisma Therapeutics CARM Stock Holding History

Summit Securities Group’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,210
Closed -$8K – 609
2024
Q2 		$8K Buy
+5,210
New +$7.77K ﹤0.01% 454

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Summit Securities Group's CARM Position: Q3 2024 in Review

Summit Securities Group sold out of Carisma Therapeutics (CARM) in Q3 2024, closing a stake of 5,210 shares — an estimated $8K sold.

Summit Securities Group first reported a position in CARM in Q2 2024 and held it in 1 quarter. The position peaked at $8K in Q2 2024. 37 funds tracked by Wall St. Rank hold CARM as of Q3 2024.

  • Summit Securities Group reported no remaining Carisma Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Summit Securities Group sold 5,210 Carisma Therapeutics shares in Q3 2024, an estimated $8K.
  • Summit Securities Group first reported a position in Carisma Therapeutics in Q2 2024 and held it in 1 quarter.
  • Summit Securities Group's Carisma Therapeutics position peaked at $8K in Q2 2024.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2024.

Based on Summit Securities Group's 13F filing for Q3 2024, filed 7 Nov 2024.